sulfate) is a prescription medication approved to treat adults with a specific type of cancer of the blood and bone marrow known as Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia
(ALL). The medication is approved for use in people whose cancer has returned or gotten worse after treatment with at least two other anti-leukemia therapies.
Who Makes This Medication?
Marqibo comes as a kit containing different vials that are combined to prepare the final medication. The individual components of the kit are made by different manufacturers, including Hospira Australia Pty, Ltd., Cangene Corporation, and Jubilant HollisterStier. The kit is packaged by Anderson Packaging, Inc. Marqibo is distributed by Talon Therapeutics, Inc.
Marqibo belongs to a group of medicines known as vinca alkaloids. Vinca alkaloids are also called antimicrotubule agents because they affect microtubules, which are proteins within cells that help cells divide and multiply.
Marqibo works by binding to tubulin, a protein that makes up microtubules. When bound to tubulin, Marqibo alters the structure of microtubules, preventing them from functioning normally. As a result, the altered microtubules cannot help cells divide. This stops the cells' growth and causes the cells to die.
Marqibo can kill both cancer cells and healthy cells, which is what causes many of the dangerous side effects. However, it has a greater effect on cells that rapidly multiply. Generally, cancer cells multiply more rapidly than healthy cells and are, therefore, more affected by Marqibo treatment.
The active ingredient in Marqibo, vincristine
, is contained in tiny particles of fat (liposomes). This changes how the medication is processed in the body. Marqibo stays in the body longer than nonliposomal vincristine (Vincasar PFS®
). It is thought to be more effective than Vincasar PFS and to have fewer side effects.